150 related articles for article (PubMed ID: 1901030)
1. In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer.
Nio Y; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Imai S; Tobe T
Cancer Immunol Immunother; 1991; 32(6):335-41. PubMed ID: 1901030
[TBL] [Abstract][Full Text] [Related]
2. In vitro reactivity to a protein-bound polysaccharide PSK of peripheral blood lymphocytes from patients with gastrointestinal cancer.
Sugimachi K; Maehara Y; Kusumoto T; Okamura T; Korenaga D; Kohnoe S; Baba H; Anai H
Anticancer Res; 1995; 15(5B):2175-9. PubMed ID: 8572620
[TBL] [Abstract][Full Text] [Related]
3. Activation by the protein-bound polysaccharide PSK (krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer.
Mizutani Y; Yoshida O
J Urol; 1991 May; 145(5):1082-7. PubMed ID: 2016797
[TBL] [Abstract][Full Text] [Related]
4. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and tumor-infiltrating lymphocytes activated by PSK.
Kariya Y; Okamoto N; Fujimoto T; Inoue N; Kihara T; Sugie K; Yagita M; Kanzaki H; Mori T; Uchida A
Jpn J Cancer Res; 1991 Sep; 82(9):1044-50. PubMed ID: 1938599
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer.
Nio Y; Tsubono M; Tseng CC; Morimoto H; Kawabata K; Masai Y; Shiraishi T; Imai S; Ohgaki K; Tobe T
Biotherapy; 1992; 4(2):117-28. PubMed ID: 1622733
[TBL] [Abstract][Full Text] [Related]
6. PSK, a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumor-derived factors in vitro.
Okuzawa M; Shinohara H; Kobayashi T; Iwamoto M; Toyoda M; Tanigawa N
Int J Oncol; 2002 Jun; 20(6):1189-95. PubMed ID: 12011998
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of antitumor cytotoxicity of hepatic lymphocytes by oral administration of PSK.
Yunoki S; Tanaka N; Hizuta A; Orita K
Int J Immunopharmacol; 1994 Feb; 16(2):123-30. PubMed ID: 8181901
[TBL] [Abstract][Full Text] [Related]
8. Effect of PSK and its subfractions on peripheral blood lymphocytes mediated cytotoxicity against urinary bladder tumor cells.
Mizutani Y; Nio Y; Yoshida O
J Urol; 1992 Nov; 148(5):1571-6. PubMed ID: 1433570
[TBL] [Abstract][Full Text] [Related]
9. Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphocytes in vitro.
Noguchi K; Tanimura H; Yamaue H; Tsunoda T; Iwahashi M; Tani M; Mizobata S; Hotta T; Arii K; Tamai M
Anticancer Res; 1995; 15(2):255-8. PubMed ID: 7762991
[TBL] [Abstract][Full Text] [Related]
10. Activation of human natural killer cells by the protein-bound polysaccharide PSK independently of interferon and interleukin 2.
Kariya Y; Inoue N; Kihara T; Okamoto N; Sugie K; Mori T; Uchida A
Immunol Lett; 1992 Feb; 31(3):241-5. PubMed ID: 1372283
[TBL] [Abstract][Full Text] [Related]
11. Protein-bound polysaccharide K augments IL-2 production from murine mesenteric lymph node CD4+ T cells by modulating T cell receptor signaling.
Asai H; Iijima H; Matsunaga K; Oguchi Y; Katsuno H; Maeda K
Cancer Immunol Immunother; 2008 Nov; 57(11):1647-55. PubMed ID: 18343922
[TBL] [Abstract][Full Text] [Related]
12. PSK and OK-432-induced immunomodulation of inducible nitric oxide (NO) synthase gene expression in mouse peritoneal polymorphonuclear leukocytes and NO-mediated cytotoxicity.
Asai K; Kato H; Hirose K; Akaogi K; Kimura S; Mukai S; Inoue M; Yamamura Y; Sano H; Sugino S; Yoshikawa T; Kondo M
Immunopharmacol Immunotoxicol; 2000 May; 22(2):221-35. PubMed ID: 10952028
[TBL] [Abstract][Full Text] [Related]
13. Plant polysaccharide PSK: cytostatic effects on growth and invasion; modulating effect on the expression of HLA and adhesion molecules on human gastric and colonic tumor cell surface.
Iguchi C; Nio Y; Takeda H; Yamasawa K; Hirahara N; Toga T; Itakura M; Tamura K
Anticancer Res; 2001; 21(2A):1007-13. PubMed ID: 11396133
[TBL] [Abstract][Full Text] [Related]
14. Effects of PSK on interleukin-2 production by peripheral lymphocytes of patients with advanced ovarian carcinoma during chemotherapy.
Kikuchi Y; Kizawa I; Oomori K; Iwano I; Kita T; Kato K
Jpn J Cancer Res; 1988 Jan; 79(1):125-30. PubMed ID: 3128500
[TBL] [Abstract][Full Text] [Related]
15. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy.
Fisher M; Yang LX
Anticancer Res; 2002; 22(3):1737-54. PubMed ID: 12168863
[TBL] [Abstract][Full Text] [Related]
16. In vitro augmentation of cytotoxic activity of peripheral blood lymphocytes and spleen cells of cancer patients by ubenimex.
Iwahashi M; Tanimura H; Yamaue H; Tsunoda T; Tani M; Noguchi K; Mizobata S; Tamai M; Hotta T; Arii K
Anticancer Res; 1994; 14(4A):1557-62. PubMed ID: 7979185
[TBL] [Abstract][Full Text] [Related]
17. Effect of Krestin (PSK) on the induction of IL-2 activated killer cells.
Sakamaki S; Kohgo Y; Nojiri S; Kanisawa Y; Ito Y; Takahashi M; Ueno Y; Hirayama Y; Niitsu Y
Jpn J Clin Oncol; 1992 Apr; 22(2):79-83. PubMed ID: 1619782
[TBL] [Abstract][Full Text] [Related]
18. Protein-bound polysaccharide-K reduces the proportion of regulatory T cells in vitro and in vivo.
Aoki R; Iijima H; Kato M; Uchida M; Wada T; Murata M; Ogawa K; Naritaka Y; Yoshimatsu K
Oncol Rep; 2014 Jan; 31(1):50-6. PubMed ID: 24190620
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of effector cell activities in mice bearing syngeneic plasmacytoma X5563 by a biological response modifier, PSK.
Matsunaga K; Iijima H; Aota M; Oguchi Y; Fujii T; Yoshikumi C; Nomoto K
J Clin Lab Immunol; 1992 Jan; 37(1):21-37. PubMed ID: 1339233
[TBL] [Abstract][Full Text] [Related]
20. The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumour cells.
Vánky F; Wang P; Klein E
Cancer Immunol Immunother; 1992; 35(3):193-8. PubMed ID: 1638556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
